# Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy

> **NCT06377072** · PHASE3 · COMPLETED · sponsor: **Shanghai Hutchison Pharmaceuticals Limited** · enrollment: 428 (actual)

## Conditions studied

- Cervical Spondylotic Myelopathy

## Interventions

- **DRUG:** Shenqi Sherong Pill
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06377072
- **Lead sponsor:** Shanghai Hutchison Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-11
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-01-14
- **Target enrollment:** 428 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06377072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06377072, "Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06377072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*